Blincyto (blinatumomab) / Astellas, Amgen 
Welcome,         Profile    Billing    Logout  
 29 Diseases   78 Trials   78 Trials   3559 News 


«12...910111213141516171819...4445»
  • ||||||||||  PIT565 / Novartis
    PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies (Hall D (Ernest N. Morial Convention Center)) -  Nov 4, 2022 - Abstract #ASH2022ASH_2197;    
    P1
    Taken together, the findings from the preclinical studies suggest that PIT565 may achieve deeper and more durable responses compared to competitor CD3 bispecifics. First-in-human trial of PIT565 (NCT05397496) has been initiated and will be conducted in patients who are diagnosed with relapsed and/or refractory adult NHL after receiving two or more lines of chemotherapy and patients with relapsed and/or refractory B-ALL.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols (ENMCC - 243-245) -  Nov 4, 2022 - Abstract #ASH2022ASH_1345;    
    P=N/A, P4
    The backbone included: Pre-phase (Dexa, Cyclo), induction I (Dexa, VCR, Idarubicine), induction II (Cyclo, AraC), ±post-induction PEG-ASP, consolidation (C) cycles with IDMTX (± E.coli ASP), HDAraC (earlier: VM26), reinduction (VCR, Idarubicine, Cyclo, AraC), ± Rituximab in CD20+, i.th...The latest protocol (from 2017) additionally included IDMTX/PEG-ASP in consolidation and recommended MRD-based treatment modification (Blinatumomab in B-Lin and Nelarabin in T-Lin) in molecular failure (MolFail) after C2 (group 2)...Together with more intensive consolidation including PEG-ASP this modification likely contributed to the improved outcome with 62% OS in the youngest cohort (56-65 yrs) in group 2. In all older pts, but specifically in those >65-75 yrs or with multiple comorbidities, alternative protocols with targeted therapies and further step-wise reduction of chemotherapy require prospective exploration in clinical trials with the major goal to reduce ED rate and to improve MRD response.
  • ||||||||||  Review, Journal:  Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia. (Pubmed Central) -  Oct 31, 2022   
    Regimens including venetoclax in myeloid BP or inotuzumab ozogamicin or blinatumomab in lymphoid BP might lead to deeper and longer responses, facilitating potentially curative allo-SCT for patients with CML-BP once CP is achieved. Newer agents and novel combination therapies are further expanding the therapeutic arsenal in advanced phase CML.
  • ||||||||||  Review, Journal:  Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas. (Pubmed Central) -  Oct 28, 2022   
    Off-label therapies inotuzumab ozogamicin, brentuximab vedotin, and venetoclax demonstrate low rates of treatment-related grade ≥3 infections, while the addition of bortezomib to standard chemotherapy in T-cell malignancies seems to decrease the infection risk during induction. Prophylaxis, immune reconstitution, and vaccinations for each targeted agent are discussed, along with comparisons to adult studies.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL. (Pubmed Central) -  Oct 25, 2022   
    The bispecific T-cell engager (BiTE) blinatumomab against CD19 and CD3 has emerged as the most successful bispecific antibody (bsAb) to date; however, a significant proportion of patients do not respond to the treatments or eventually experience relapse after an initial response, and the recurrence rate increases significantly due to escape or downregulation of the CD19 antigen...In addition, tsAb treatment can lead to the long-term elimination of primary B-ALL patient samples in the PDX model and significantly prolong survival. This novel approach provides unique insight into the structural optimization of T-cell-redirected multispecific antibodies using site-specific recombination and may be broadly applicable to heterogeneous and resistant tumor populations as well as solid tumors.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia. (Pubmed Central) -  Oct 25, 2022   
    This novel approach provides unique insight into the structural optimization of T-cell-redirected multispecific antibodies using site-specific recombination and may be broadly applicable to heterogeneous and resistant tumor populations as well as solid tumors. No abstract available
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement. (Pubmed Central) -  Oct 20, 2022   
    Among them, blinatumomab has been successfully used to treat CD19 positive malignancies and has been approved by the FDA as standard care for acute lymphoblastic leukemia (ALL)...We focus on analyzing reports from clinical trials and preclinical studies, and summarize the factors that have been identified to impact the efficacy of T-BsAbs. Lastly, we review current and propose new approaches to improve the clinical efficacy of T-BsAbs.
  • ||||||||||  Novel Anti-Cancer Agents and Capillary Leak Syndrome (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_1085;    
    Other agents such as bortezomib, anti VEGF agents , trastuzumab and ICIs(mainly nivolumab and ipiliumumab) can also rarely cause CLS. Oncologist and nephrologists need to be mindful of this rare fatal side effect.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Journal:  Recent progress of bispecific antibody-based therapy for hematological malignancies (Pubmed Central) -  Oct 13, 2022   
    After the success of blinatumomab for treating refractory B-cell leukemia, series of clinical trials using bispecific antibodies for relapsed and refractory hematological malignancies are being conducted...In the future, combination therapy of conventional chemotherapy and/or allogeneic stem-cell transplantation with bispecific antibody therapy will be necessary. Furthermore, molecular target therapy with bispecific antibody therapy is expected to pave the way for next-generation target therapy, resulting in the development of a further effective and safe treatment strategy for hematological malignancies.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    Enrollment open, Trial completion date, Trial primary completion date:  Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) -  Oct 12, 2022   
    P=N/A,  N=60, Recruiting, 
    Consolidation with blinatumomab in patients with newly diagnosed, high-risk DLBCL who did not progress under R-chemotherapy was better tolerated than in previous studies where blinatumomab was used for treatment of patients with lymphoma. Not yet recruiting --> Recruiting | Trial completion date: Mar 2023 --> May 2024 | Trial primary completion date: Mar 2023 --> May 2024
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen
    A ROR1 specific CD3 bispecific T-cell Engager engineered for solid tumors with an expanded therapeutic window (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1376;    
    In the context of JeKo1 CD19+/ROR1+ tumor targets, the 5A1 TCEs were 6-7.5 fold better decoupled compared to blinatumomab...The concentration of TCEs required for maximum IFNg release and killing of tumor cells registered in the pM range, as opposed to the supraphysiologic nM/uM range that was insufficient to induce more than 25% and 35% of IFNg release and cytotoxicity, respectively, on cells expressing <10,000 molecules of ROR1. Conclusions We hypothesize, that our ROR1 TCEs will provide a superior therapeutic index and safety profile associated with reduced risks of CRS and TLS, the capacity to dose higher, avoid continuous infusion and potentially mediate better efficacy in solid tumors.
  • ||||||||||  Blincyto (blinatumomab) / Astellas, Amgen, Lunsumio (mosunetuzumab) / Roche, Biogen
    EVOLVETM: a novel costimulatory T cell engager platform engineered for the treatment of immune suppressive tumors (Hall C) -  Oct 6, 2022 - Abstract #SITC2022SITC_1368;    
    We also demonstrate the modular nature of the EVOLVE platform across diverse tumor antigens including B7H4 (VTCN1), the B cell lymphoma antigen CD20 and a novel squamous tumor antigen ULBP2. Conclusions Our data highlight the broad applications of the EVOLVE platform to improve CD8 T cell-mediated anti-tumor immunity and suggest its potential as an emerging, first-in-category immunotherapeutic strategy to address unmet medical needs in oncology.